BillionToOne, a Menlo Park, CA-based precision diagnostics firm, raised $130M in Collection D funding at an over $1B+ valuation.
The spherical was led by Premji Make investments, with participation by one other incoming investor, Neuberger Berman, in addition to by current traders, together with Adam Road Companions, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, and Fifty Years. Akshay Rai, who has led the Collection D spherical, is becoming a member of BillionToOne’s Board of Administrators,
The corporate intends to make use of the funds to develop and scale its prenatal and oncology companies.
BillionToOne is a precision diagnostics firm whose patented Quantitative Counting Expertise™ (QCT™) molecular counting platform is a multiplex expertise that may depend DNA molecules on the single-molecule degree. Its complementary oncology liquid biopsy merchandise, Northstar Choose® and Northstar Response®, allow clinicians to pick the fitting therapies and monitor sufferers’ responses to therapies, notably in late-stage most cancers sufferers. Northstar Choose® achieves a 2-5x decrease restrict of detection in comparison with different assays available on the market, and Northstar Response® is a methylation-based ctDNA assay with 10x precision than SNV-based assays, validated throughout completely different most cancers varieties to evaluate the remedy response in late-stage most cancers sufferers.
Over 500K sufferers have obtained BillionToOne checks up to now, and the corporate has grown from $0M to $125M ARR within the final ~4 years.
FinSMEs
22/06/2024
